India: Food and Drugs Law

This comprehensive newsletter examines critical regulatory developments across Legal Metrology, Food Safety, and Agricultural Laws in India during June 2026. From e-commerce country-of-origin filters and fuel dispenser verification reforms to FSSAI's digital compliance initiatives and nano-fertilizer frameworks, the edition covers essential updates impacting manufacturers, exporters, food business operators, and agri-businesses navigating India's evolving regulatory landscape.

India's life sciences and healthcare sector continues to evolve through significant regulatory and policy developments in June 2026. Key changes include pharmacovigilance mandates, prohibition of irrational drug combinations, expanded QR code authentication requirements, cosmetics compliance directions, ART and surrogacy clinic renewal frameworks, safe injection practice mandates, drug price control reforms, and new ambulance service guidelines that reshape pharmaceutical, biotechnology, medical devices, an

India's pharmaceutical patent system navigates the delicate balance between protecting innovation and ensuring affordable access to life-saving medicines for millions living in poverty. Through mechanisms like compulsory licensing and restrictions on patent evergreening, the country attempts to honor its TRIPS obligations while maintaining its role as the "Pharmacy of the World." How effectively do these legal safeguards reconcile the competing interests of global pharmaceutical giants and public health nee

In this episode of Podcast Bites by IndiaLaw LLP, host Tanvi Dalvi unpacks the sweeping reforms introduced under the FSSAI 2026 Amendment Regulations, effective 1 April 2026.

India's life sciences and healthcare sector saw significant regulatory shifts in April 2026, including proposed decriminalization of minor violations, new medical device testing fees, and streamlined foreign training requirements for healthcare professionals. Courts also delivered key rulings on pharmaceutical trademark disputes, reinforcing stricter standards for drug name similarity.

Semaglutide, sold under the blockbuster brands Ozempic and Wegovy, has become one of the most talked-about drugs in recent memory. It belongs to a class of medicines known as GLP-1 receptor agonists, which mimic a hormone that regulates appetite and blood sugar.

In Zydus Lifesciences Ltd. v. E.R. Squibb and Sons LLC & Ors. (FAO(OS) (COMM) 120/2025, CM APPL. 44383/2025, CM APPL. 44386/2025 & CM APPL. 44388/2025), the Division Bench of the Delhi High Court modified the interim order passed by the Single Judge, who had restrained Zydus from manufacturing, using, offering for sale, selling or importing its biosimilar version of the cancer immunotherapy drug Nivolumab in India.

A masala dosa served for ₹100 looks deceptively simple. But behind that single plate lies an entire economy farmers, miners, refiners, manufacturers, logistics operators, warehouses, and restaurants, each link governed by a distinct legal architecture.

On March 25, 2026, the National Pharmaceutical Pricing Authority (NPPA), operating under the aegis of the Ministry of Chemicals and Fertilizers (Department of Pharmaceuticals), Government of India...